SecBot SecBot
DEFA14A ·Filed Aug 3, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 5/10
Horizondays Processed3mo ago SEC0001140361-26-030996
Proxy solicitation materials
Actionable Insight ▲ Bullish

With the special meeting just eight days away and non-voting holders already consenting, the probability of stockholder approval is high. The voluntary supplemental disclosures further reduce deal-closing litigation risk. Traders should monitor the August 11 vote outcome and subsequent regulatory milestones (Australian ACCC Phase 1 expiring September 7). The stock should trade near the $135.11 consideration minus time value and any residual risk of delay. Any widening of the spread would signal increased uncertainty.

DirectionBullish
Confidencehigh
Horizondays

Drugs in focus

APGE drug pipeline →

zumilokibart

◆ Mixed Named in this DEFA14A
Impact
Phase
Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
Time to market
Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
Next catalyst
None dated

What to watchFor APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$134.19
T+0 close · Aug 3, 2026 · via day close
Latest settled
+0.66%
T+20 · $135.08
Vs SPY
+1.90%
α at T+20
Next horizon
T+60
due 20d ago
  1. T+0 · Aug 4 $134.19entry
  2. T+1 · 3mo ago +0.03%α +0.23% · $134.23
  3. T+5 · 3mo ago +0.37%α +0.47% · $134.69
  4. T+20 · 3mo ago +0.66%α +1.90% · $135.08
  5. T+60 · due 20d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 special meeting to vote on the $135.11/share all-cash acquisition by AbbVie. The supplement addresses a pending stockholder lawsuit (Smith Complaint) alleging inadequate disclosures, adds voluntary disclosures on financial projections and fairness opinions, and confirms German antitrust clearance (FCO) was obtained on July 27, 2026, with an Australian ACCC filing underway. The board reiterates its unanimous recommendation for approval, and non-voting stock holders have already consented. The deal remains on track with the record-date share count updated to 62,140,183 voting shares outstanding; a majority of 31,070,092 votes is needed for approval.

Key Financial Metrics

Vote
merger approval
Meeting
2026-08-11

Key Facts

  • Merger consideration is $135.11 per share in cash, with Apogee stockholders to receive that amount upon closing
  • Special meeting of stockholders to vote on the merger is scheduled for August 11, 2026 at 9:00 a.m. Eastern time
  • As of the record date (July 10, 2026), there were 62,140,183 shares of voting common stock outstanding; directors and officers beneficially owned 1,412,999 shares (2.27%)
  • Majority approval requires 31,070,092 affirmative votes; non-voting common stock holders have already delivered written consent to the merger
  • One complaint filed in New York state court (Timothy Smith v. Apogee et al.) alleging inadequate disclosures; Apogee believes claims are without merit and is voluntarily making supplemental disclosures to mitigate litigation risk
  • German Federal Cartel Office (FCO) provided unconditional clearance for the merger on July 27, 2026; an Australian ACCC notification was filed on the same date with a Phase 1 review period expiring September 7, 2026
  • Goldman Sachs illustrative DCF analysis implied a per-share value range of $98.90 to $119.20; Jefferies precedent transactions analysis implied $117.65 to $151.35, with the $135.11 consideration falling within that range
  • Management projections (2026-2046) show net sales beginning in 2029 ($106M) and rising to a peak of approximately $9.3B in 2038, driven by zumilokibart (APG777) for atopic dermatitis, eosinophilic esophagitis, and asthma, plus APG279
  • Apogee had $1.358 billion in cash and cash equivalents and zero debt as of the valuation date, as used in Goldman Sachs’ DCF analysis
  • Updated golden parachute compensation totals: CEO Michael Henderson ~$61.3M, Carl Dambkowski ~$25.6M, Jane Pritchett Henderson ~$25.3M (including equity, cash, perquisites, and tax reimbursement)

Financial Impact

Merger consideration of $135.11/share represents a significant premium over pre-announcement levels; implied enterprise value is approximately $10B+ based on $1.358B cash and zero debt. Management projects peak annual net sales of ~$9.3B by 2038.

stock price (merger premium)shareholder cash considerationenterprise valuenet sales (projected)cash and cash equivalents

Risk Factors

  • The pending Smith Complaint could seek to delay or enjoin the merger, though Apogee believes the claims are without merit and is making supplemental disclosures to address them
  • Failure to obtain remaining regulatory clearances (Australian ACCC, possibly others) could delay or prevent closing
  • If a superior proposal emerges, Apogee's board could change its recommendation, though the merger agreement includes customary deal protection provisions
  • Stockholder approval requires a majority of outstanding voting shares; abstentions and broker non-votes effectively count as votes against, creating a small risk of disapproval if turnout is low

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
33% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-030996
Document: 0001140361-26-030996-index-headers.html0001140361-26-030996
Document: 0001140361-26-030996-index.html0001140361-26-030996
Document: 0001140361-26-030996.txt0001140361-26-030996

Track record

31 reports on APGE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Viewing Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026